Evidence map›Paper›PMID 22087282›Full record

ArticlePloS one2011

Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging.

Chera L Maarouf, Ian D Daugs, Tyler A Kokjohn, Douglas G Walker, Jesse M Hunter, Jane C Kruchowsky, Randy Woltjer, Jeffrey Kaye, Eduardo M Castaño, Marwan N Sabbagh and 2 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Chera L MaaroufThe Longtine Center for Neurodegenerative Biochemistry, Banner Sun Health Research Institute, Sun City, Arizona, United States of America.
Ian D Daugs
Tyler A Kokjohn
Douglas G Walker
Jesse M Hunter
Jane C Kruchowsky
Randy Woltjer
Jeffrey Kaye
Eduardo M Castaño
Marwan N Sabbagh
Thomas G Beach
Alex E Roher
Banner Sun Health Research Institute · USOregon Health & Science University · USFundación Instituto Leloir · ARMidwestern University · US

Funding

RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI GONZALEZ HERNANDEZ, GRACIELA · 2001 to 2020
$32.5M
APP/AB/Tau biochemistry in transgenic mice, familial and sporadic ADR01AG019795 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI ROHER, ALEX E · 2001 to 2013
$3.8M
Are the suppressors of cytokine signaling involved in Alzheimer's disease?R21AG034409 · NIA · BANNER SUN HEALTH RESEARCH INSTITUTE · PI WALKER, DOUGLAS GORDON · 2010 to 2011
$397k
Beta-amyloid peptides in the oldest-old: A biochemical profile of successful aginR21AG035078 · NIA · BANNER SUN HEALTH RESEARCH INSTITUTE · PI ROHER, ALEX E · 2010 to 2011
$397k
NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG19610NIA NIH HHS R01 AG019795NIA NIH HHS R21 AG034409NIA NIH HHS R21 AG035078NIA NIH HHS U19 AG010483
6 · The paper itself

Abstract

The amyloid cascade hypothesis provides an economical mechanistic explanation for Alzheimer's disease (AD) dementia and correlated neuropathology. However, some nonagenarian individuals (high pathology controls, HPC) remain cognitively intact while enduring high amyloid plaque loads for decades. If amyloid accumulation is the prime instigator of neurotoxicity and dementia, specific protective mechanisms must enable these HPC to evade cognitive decline. We evaluated the neuropathological and biochemical differences existing between non-demented (ND)-HPC and an age-matched cohort with AD dementia. The ND-HPC selected for our study were clinically assessed as ND and possessed high amyloid plaque burdens. ELISA and Western blot analyses were used to quantify a group of proteins related to APP/Aβ/tau metabolism and other neurotrophic and inflammation-related molecules that have been found to be altered in neurodegenerative disorders and are pivotal to brain homeostasis and mental health. The molecules assumed to be critical in AD dementia, such as soluble or insoluble Aβ40, Aβ42 and tau were quantified by ELISA. Interestingly, only Aβ42 demonstrated a significant increase in ND-HPC when compared to the AD group. The vascular amyloid load which was not used in the selection of cases, was on the average almost 2-fold greater in AD than the ND-HPC, suggesting that a higher degree of microvascular dysfunction and perfusion compromise was present in the demented cohort. Neurofibrillary tangles were less frequent in the frontal cortices of ND-HPC. Biochemical findings included elevated vascular endothelial growth factor, apolipoprotein E and the neuroprotective factor S100B in ND-HPC, while anti-angiogenic pigment epithelium derived factor levels were lower. The lack of clear Aβ-related pathological/biochemical demarcation between AD and ND-HPC suggests that in addition to amyloid plaques other factors, such as neurofibrillary tangle density and vascular integrity, must play important roles in cognitive failure.

Indexed as

Aged, 80 and overAgingAlzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorCase-Control StudiesCognition DisordersDementiaEnzyme-Linked Immunosorbent AssayFemaleHumansMaleNeurofibrillary Tanglestau ProteinsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAPP protein, humantau Proteins

Identifiers

PMID22087282
PMCPMC3210154
OpenAlexW2037677220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.